 |
Founded in 1942 by Dr. Nejat F. Eczacıbaşı, the Eczacıbaşı Group takes its
name from the honorary title "chief pharmacist", conferred on the father
of Dr. Eczacıbaşı at the turn of the last century. Eczacıbaşı is a
prominent Turkish industrial group with 42 companies, close to 9,900 employees and
as of end-2007 a combined net turnover of $ 3.2 billion.
Eczacıbaşı's core sectors are pharmaceuticals, building products and
consumer products. Additionally, the Group is active in finance,
information technology, welding technology and real estate. In Turkey,
Eczacıbaşı is the leader in most of its businesses and has distribution
networks for pharmaceuticals, building products and fast-moving consumer
goods that are among the strongest in their sectors. Internationally,
Eczacıbaşı is best known for its flagship VitrA brand, a powerful
contender in global bathroom and tile markets. It is also a major exporter
of tissue paper, pharmaceuticals, welding electrodes, electronic smart
cards and industrial raw materials such as clay and feldspar.
International partnership is a central component of the Eczacıbaşı Group's
growth strategy. Eczacıbaşı has 10 international joint ventures and
numerous cooperation agreements with leading international companies. All of these are grounded on the principle of long-term mutual benefit, based
on firm business criteria and ethical business practices.
The Eczacıbaşı Group's mission is to be a pioneer of modern, high quality
and healthy lifestyles. Accordingly, the Group encourages each of its
companies to surpass established standards in their sectors and raise
consumer benchmarks of product and service quality. Through sponsorship
and responsible corporate practices, it also promotes social and economic
development that nurtures cultural and scientific activity, protects the
environment and preserves scarce natural resources.
www.eczacibasi.com.tr
. 64 manufacturing facilities in 27 countries
. Activities in more than 110 countries
. 48 thousand employees
. 2004 sales: 9,5 billion USD
. R&D expenditures (2004): 517 million USD
. 25% of the world parenteral solutions market
. 50% of the American parenteral solutions market
Baxter has provided a number of products and services in the field of medicine
ranging from the first commercially manufactured intravenous (IV) solutions to
the first commercially manufactured artificial kidney, valve,
HomeChoice dialysis device that cleans the blood of the patient
through the night, automatic blood cell separation system and treatment of
hemophilia patients with genetic engineering methods for the first time.
50% of the sales income of Baxter is gained from outside USA and its products
are being sold in more than 110 countries.
Baxter is operating in five different geographical regions as
America, Canada, Intercontinental/Asia, Europe and Japan. And Turkey is
included among Intercontinental/Asia group composed of
countries such as Mexico, Australia, Brasilia, Chile, Argentine, Colombia,
Japan and China.
Most of the products are manufactured by state of the art technology and
manufacturing in all the facilities of Baxter is continued with the highest
quality standards.
Baxter has more than 48,000 talented employees all over the
world who commit themselves to their jobs and who work with the aim of
increasing the life quality of as many people as possible.
www.baxter.com
|
|